User login
Key clinical point: Quizartinib-based combinations were effective and well tolerated in both frontline and first salvage for patients with untreated myelodysplastic syndrome (MDS) and FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML).
Major finding: Frontline quizartinib/azacitidine vs. quizartinib/low-dose cytarabine (LDAC) led to a higher proportion of patients achieve composite response (87% vs. 74%) and a longer overall survival (19.2 vs. 8.5 months; P = .036). Similarly, quizartinib/azacitidine vs. quizartinib/LDAC was associated with a higher proportion of patients with relapsed/refractory AML achieve composite response (64% vs. 29%) and a trend for longer overall survival (12.8 vs. 4 months; P = .053). Overall, therapy was well tolerated in both cohorts.
Study details: In this open-label phase I/II trial, patients with untreated MDS/AML or those receiving first-salvage treatment for FLT3-ITD AML were treated with a combination of quizartinib and either azacitidine or LDAC in frontline (n=34) or as first-salvage (n=39) therapy.
Disclosures: The study was supported in part by the Cancer Center Support Grant. The authors declared no competing financial interests.
Source: Swaminathan M et al. Haematologica. 2021 Apr 15. doi: 10.3324/haematol.2020.263392.
Key clinical point: Quizartinib-based combinations were effective and well tolerated in both frontline and first salvage for patients with untreated myelodysplastic syndrome (MDS) and FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML).
Major finding: Frontline quizartinib/azacitidine vs. quizartinib/low-dose cytarabine (LDAC) led to a higher proportion of patients achieve composite response (87% vs. 74%) and a longer overall survival (19.2 vs. 8.5 months; P = .036). Similarly, quizartinib/azacitidine vs. quizartinib/LDAC was associated with a higher proportion of patients with relapsed/refractory AML achieve composite response (64% vs. 29%) and a trend for longer overall survival (12.8 vs. 4 months; P = .053). Overall, therapy was well tolerated in both cohorts.
Study details: In this open-label phase I/II trial, patients with untreated MDS/AML or those receiving first-salvage treatment for FLT3-ITD AML were treated with a combination of quizartinib and either azacitidine or LDAC in frontline (n=34) or as first-salvage (n=39) therapy.
Disclosures: The study was supported in part by the Cancer Center Support Grant. The authors declared no competing financial interests.
Source: Swaminathan M et al. Haematologica. 2021 Apr 15. doi: 10.3324/haematol.2020.263392.
Key clinical point: Quizartinib-based combinations were effective and well tolerated in both frontline and first salvage for patients with untreated myelodysplastic syndrome (MDS) and FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML).
Major finding: Frontline quizartinib/azacitidine vs. quizartinib/low-dose cytarabine (LDAC) led to a higher proportion of patients achieve composite response (87% vs. 74%) and a longer overall survival (19.2 vs. 8.5 months; P = .036). Similarly, quizartinib/azacitidine vs. quizartinib/LDAC was associated with a higher proportion of patients with relapsed/refractory AML achieve composite response (64% vs. 29%) and a trend for longer overall survival (12.8 vs. 4 months; P = .053). Overall, therapy was well tolerated in both cohorts.
Study details: In this open-label phase I/II trial, patients with untreated MDS/AML or those receiving first-salvage treatment for FLT3-ITD AML were treated with a combination of quizartinib and either azacitidine or LDAC in frontline (n=34) or as first-salvage (n=39) therapy.
Disclosures: The study was supported in part by the Cancer Center Support Grant. The authors declared no competing financial interests.
Source: Swaminathan M et al. Haematologica. 2021 Apr 15. doi: 10.3324/haematol.2020.263392.